{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T23:58:06Z","timestamp":1792627086356,"version":"4.5.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,2,21]],"date-time":"2023-02-21T00:00:00Z","timestamp":1676937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,2,21]],"date-time":"2023-02-21T00:00:00Z","timestamp":1676937600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"DOI":"10.1007\/s00403-023-02577-7","type":"journal-article","created":{"date-parts":[[2023,2,21]],"date-time":"2023-02-21T21:19:18Z","timestamp":1677014358000},"page":"1697-1703","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Immune checkpoint inhibitor-induced vitiligo in cancer patients: characterization and management"],"prefix":"10.1007","volume":"315","author":[{"given":"Jonathan","family":"Lo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6155-2226","authenticated-orcid":false,"given":"Hannah L.","family":"Hanania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2990-9456","authenticated-orcid":false,"given":"Monika F.","family":"Keiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5372-784X","authenticated-orcid":false,"given":"Anisha B.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,21]]},"reference":[{"issue":"5","key":"2577_CR1","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/j.jaad.2020.03.132","volume":"83","author":"AN Geisler","year":"2020","unstructured":"Geisler AN, Phillips GS, Barrios DM et al (2020) Immune checkpoint inhibitor-related dermatologic adverse events. J Am Acad Dermatol 83(5):1255\u20131268. https:\/\/doi.org\/10.1016\/j.jaad.2020.03.132","journal-title":"J Am Acad Dermatol"},{"issue":"22","key":"2577_CR2","doi-asserted-by":"publisher","first-page":"5731","DOI":"10.3390\/ijms20225731","volume":"20","author":"CM Failla","year":"2019","unstructured":"Failla CM, Carbone ML, Fortes C, Pagnanelli G, D\u2019Atri S (2019) Melanoma and vitiligo in: good company. Int J Mol Sci 20(22):5731. https:\/\/doi.org\/10.3390\/ijms20225731","journal-title":"Int J Mol Sci"},{"issue":"52","key":"2577_CR3","doi-asserted-by":"publisher","first-page":"e13810","DOI":"10.1097\/MD.0000000000013810","volume":"97","author":"C Lolli","year":"2018","unstructured":"Lolli C, Medri M, Ricci M et al (2018) Vitiligo-like lesions in a patient treated with nivolumab for renal cell carcinoma. Medicine (Baltimore) 97(52):e13810. https:\/\/doi.org\/10.1097\/MD.0000000000013810","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"2577_CR4","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1111\/ced.13867","volume":"44","author":"RC Liu","year":"2019","unstructured":"Liu RC, Consuegra G, Chou S, Fernandez Pe\u00f1as P (2019) Vitiligo-like depigmentation in oncology patients treated with immunotherapies for nonmelanoma metastatic cancers. Clin Exp Dermatol 44(6):643\u2013646. https:\/\/doi.org\/10.1111\/ced.13867","journal-title":"Clin Exp Dermatol"},{"key":"2577_CR5","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.lungcan.2017.04.019","volume":"109","author":"T Uenami","year":"2017","unstructured":"Uenami T, Hosono Y, Ishijima M et al (2017) Vitiligo in a patient with lung adenocarcinoma treated with nivolumab: a case report. Lung Cancer 109:42\u201344. https:\/\/doi.org\/10.1016\/j.lungcan.2017.04.019","journal-title":"Lung Cancer"},{"issue":"6","key":"2577_CR6","doi-asserted-by":"publisher","first-page":"2614","DOI":"10.1111\/bcp.14663","volume":"87","author":"V Bulat","year":"2021","unstructured":"Bulat V, Likic R, Bradic L, Speeckaert R, Azdajic MD (2021) Pembrolizumab-induced vitiligo in a patient with lung adenocarcinoma: a case report. Br J Clin Pharmacol 87(6):2614\u20132618. https:\/\/doi.org\/10.1111\/bcp.14663","journal-title":"Br J Clin Pharmacol"},{"issue":"10","key":"2577_CR7","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1016\/j.jdcr.2018.08.009","volume":"4","author":"C Kosche","year":"2018","unstructured":"Kosche C, Mohindra N, Choi JN (2018) Vitiligo in a patient undergoing nivolumab treatment for non-small cell lung cancer. JAAD Case Rep 4(10):1042\u20131044. https:\/\/doi.org\/10.1016\/j.jdcr.2018.08.009","journal-title":"JAAD Case Rep"},{"issue":"5","key":"2577_CR8","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1111\/ced.13382","volume":"43","author":"E Rodr\u00edguez-Lomba","year":"2018","unstructured":"Rodr\u00edguez-Lomba E, Molina-L\u00f3pez I, Su\u00e1rez-Fern\u00e1ndez R, Baniandr\u00e9s-Rodr\u00edguez O (2018) Vitiligo-like lesions and immune checkpoint inhibition therapy: is it truly an adverse event exclusive to patients with melanoma? Clin Exp Dermatol 43(5):598\u2013599. https:\/\/doi.org\/10.1111\/ced.13382","journal-title":"Clin Exp Dermatol"},{"issue":"1","key":"2577_CR9","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1001\/jamadermatol.2015.2707","volume":"152","author":"C Hua","year":"2016","unstructured":"Hua C, Boussemart L, Mateus C et al (2016) Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab. JAMA Dermatol 152(1):45. https:\/\/doi.org\/10.1001\/jamadermatol.2015.2707","journal-title":"JAMA Dermatol"},{"issue":"7","key":"2577_CR10","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1200\/JCO.2014.57.4756","volume":"33","author":"H-E Teulings","year":"2015","unstructured":"Teulings H-E, Limpens J, Jansen SN et al (2015) Vitiligo-like depigmentation in patients with stage iii\u2013iv melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis. JCO 33(7):773\u2013781. https:\/\/doi.org\/10.1200\/JCO.2014.57.4756","journal-title":"JCO"},{"issue":"4","key":"2577_CR11","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1158\/1078-0432.CCR-15-1136","volume":"22","author":"M Freeman-keller","year":"2016","unstructured":"Freeman-keller M, Kim Y, Cronin H, Richards A, Gibney G, Weber JS (2016) Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes. Clin Cancer Res 22(4):886\u2013894","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2577_CR12","first-page":"560","volume":"4","author":"J Villadolid","year":"2015","unstructured":"Villadolid J, Amin A (2015) Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities. Transl Lung Cancer Res 4(5):560\u2013575","journal-title":"Transl Lung Cancer Res"},{"issue":"2","key":"2577_CR13","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1093\/annonc\/mdp325","volume":"21","author":"P Quaglino","year":"2010","unstructured":"Quaglino P, Marenco F, Osella-Abate S et al (2010) Vitiligo is an independent favourable prognostic factor in stage III and IV metastatic melanoma patients: results from a single-institution hospital-based observational cohort study. Ann Oncol 21(2):409\u2013414. https:\/\/doi.org\/10.1093\/annonc\/mdp325","journal-title":"Ann Oncol"},{"key":"2577_CR14","doi-asserted-by":"publisher","DOI":"10.1097\/DER.0000000000000670","author":"PV Karri","year":"2020","unstructured":"Karri PV, Tahseen D, Patel AB (2020) Treatment of checkpoint inhibitor-induced vitiligo in a patient with metastatic renal cell cancer. Dermatitis. https:\/\/doi.org\/10.1097\/DER.0000000000000670","journal-title":"Dermatitis"},{"issue":"1","key":"2577_CR15","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.ijwd.2017.11.005","volume":"4","author":"PE Grimes","year":"2018","unstructured":"Grimes PE, Miller MM (2018) Vitiligo: patient stories, self-esteem, and the psychological burden of disease. Int J Womens Dermatol 4(1):32\u201337. https:\/\/doi.org\/10.1016\/j.ijwd.2017.11.005","journal-title":"Int J Womens Dermatol"},{"key":"2577_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.711080","volume":"12","author":"J Seneschal","year":"2021","unstructured":"Seneschal J, Harris JE, Le Poole IC, Passeron T, Speeckaert R, Boniface K (2021) Editorial: immunology of vitiligo. Front Immunol 12:711080","journal-title":"Front Immunol"},{"key":"2577_CR17","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1016\/S1470-2045(16)30366-7","volume":"17","author":"FS Hodi","year":"2016","unstructured":"Hodi FS, Chesney J, Pavlick AC et al (2016) Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol 17:1558\u20131568. https:\/\/doi.org\/10.1016\/S1470-2045(16)30366-7","journal-title":"Lancet Oncol"},{"issue":"16","key":"2577_CR18","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","volume":"381","author":"J Larkin","year":"2019","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R et al (2019) Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 381(16):1535\u20131546. https:\/\/doi.org\/10.1056\/NEJMoa1910836","journal-title":"N Engl J Med"},{"issue":"10","key":"2577_CR19","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1200\/JCO.2013.53.0105","volume":"32","author":"SL Topalian","year":"2014","unstructured":"Topalian SL, Sznol M, McDermott DF et al (2014) Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 32(10):1020\u20131030. https:\/\/doi.org\/10.1200\/JCO.2013.53.0105","journal-title":"J Clin Oncol"},{"issue":"26","key":"2577_CR20","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Schachter J, Long GV et al (2015) Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372(26):2521\u20132532. https:\/\/doi.org\/10.1056\/NEJMoa1503093","journal-title":"N Engl J Med"},{"issue":"4","key":"2577_CR21","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1093\/annonc\/mdz011","volume":"30","author":"O Hamid","year":"2019","unstructured":"Hamid O, Robert C, Daud A et al (2019) Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. Ann Oncol 30(4):582\u2013588. https:\/\/doi.org\/10.1093\/annonc\/mdz011","journal-title":"Ann Oncol"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-023-02577-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00403-023-02577-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-023-02577-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,12]],"date-time":"2023-07-12T16:08:37Z","timestamp":1689178117000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00403-023-02577-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,21]]},"references-count":21,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,8]]}},"alternative-id":["2577"],"URL":"https:\/\/doi.org\/10.1007\/s00403-023-02577-7","relation":{},"ISSN":["1432-069X"],"issn-type":[{"value":"1432-069X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,21]]},"assertion":[{"value":"13 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was conducted under protocol PA15-0959, approved by our institutional IRB.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}